A central component of the Epidiolex marketing strategy involves highlighting the drug’s efficacy and safety profile, not its precedent-setting CBD component.
The war on cancer took a big turn with the birth of checkpoint inhibitors. Laura Entis explores their scientific and commercial impact, the unanswered questions, and what’s next for this enormously successful group of immunotherapies.
Immunotherapy’s modern era has been characterized by a tremendous amount of scientific and regulatory activity. Trace the road to the Nobel.
As pressure to address the opioid crisis mounts, pharma companies are evaluating their marketing strategies and tactics.
Spending in medical journals during the first half of 2018 may not have reached the levels seen in the recent past. At the same time, pharma companies don’t appear to be trimming their investments.
An estimated 10.7 million teens are vaping or thinking about it.
Teva’s Ajovy becomes the second approved CGRP migraine therapy, following Amgen’s Aimovig.
How does one create an effective market access program in the current healthcare environment? Experts share seven tips for success.
Amarin’s Vascepa trial is set to read out results by the end of September.
As more medications are approved, pharma companies are being pushed farther afield into a land of bizarre — but hopefully still memorable and vaguely meaningful — drug names.
Please login or register first to view this content.
